Correlation between mutation burden of tumor and immunological/clinical parameters in considering biomarkers of immune checkpoint inhibitors for non-small cell lung cancer (NSCLC).

e23184Background: There has been reported that mutation burden of solid tumor might probably be a predictive biomarker of efficacy of immune check point inhibitors, and the number of researches are...